ROUTING PLAN FOR PATIENTS WITH MALIGNANT NEOPLASMS IN A PRIVATE MEDICAL ORGANIZATION; [СХЕМА МАРШРУТИЗАЦИИ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННЫМИ НОВООБРАЗОВАНИЯМИ В ЧАСТНОЙ МЕДИЦИНСКОЙ ОРГАНИЗАЦИИ]

Introduction. Key factors affecting the quality and timeliness of detecting malignant diseases, as well as the prognosis of the disease, are the correctly performed early diagnostics and correct approach to patient routing. Aim. To analyze the algorithm for routing patients with malignant neoplasms, exemplified by a large private medical organization. Materials and Methods. A sociological survey of 412 oncologists, surgeons, proctologists and obstetricians/gynecologists employed in the clinics of JSC Medsi Group of Companies in Moscow and the Moscow Region was conducted using a specially developed questionnaire. Sociological, analytical, and mathematical-statistical research methods were used for the study. Results and Discussion. According to the survey outcomes, 72.7% of the doctors surveyed were informed about the further routing of patients with newly diagnosed malignant neoplasms, who left the contour of JSC Medsi Group of Companies. At the same time, a similar ratio was noted regardless of the special fields of the respondents. The frequency of positive responses in general also did not depend on the respondents’ work experience. At the same time, only 38.3% of doctors had feedback with patients with malignant neoplasms who left the contour of JSC Medsi Group of Companies. It was found that, in the respondents’ opinion, the chief specialist for the Oncology Project, senior oncologist of the medical group, or heads of departments could effectively control the route of a patient with a malignant neoplasm when they leave the contour of this medical organization. JSC Medsi Group of Companies has developed and implemented an effective plan (algorithm) for routing patients with suspected malignant neoplasms. When the malignant neoplasm diagnosis is morphologically confirmed in a patient, this information is automatically displayed on the oncology desktop and sent to the work e-mail of the doctor who has performed the biopsy, as well as of the head of the relevant department. When a patient moves to each of the subsequent stages of treatment or refuses to continue treatment, it is recorded on the oncology desktop of the Medialog MIS, which minimizes the likelihood of losing control over the route of the patient with a malignant neoplasm. Conclusions. Implementing the task of monitoring the correctness of routing a patient with a malignant neoplasm outside the scope of JSC GC Medsi will allow each patient with suspected oncological pathology and with an established diagnosis to timely receive medical care. © А.К. Минаева, Д.А. Лисаев, О.Е. Коновалов, А.В. Шулаев, В.И. Пак, 2024.